Hepatitis A, Viral Hepatitis Vaccines
Conditions
Keywords
Mexico, Adolescents, Hepatitis, Seroprevalence, Pertussis, Young adults
Brief summary
This study will assess the seroprevalence of hepatitis A virus (HAV), hepatitis B virus (HBV) and Bordetella pertussis (B. pertussis) in adolescents and young adults in Mexico.
Detailed description
A random sample of subjects constituting adolescents and young adults (≥10 - ≤25 years of age) will be selected from the total population that participated in the Encuesta Nacional de Salud y Nutrición (ENSANUT) 2012 in Mexico. Data (through structured questionnaires and interviews) and stored serum samples of the selected subjects obtained from the ENSANUT 2012 will be used in this study. A subset database will be designed by the National Institute of Public Health (NIPH) for the purpose of this study. Extracted data and laboratory results of the selected subjects will be captured in this database.
Interventions
OTHERData collection
Data of the selected subjects (through structured questionnaires and interviews) and stored serum samples obtained from the ENSANUT 2012. A subset database will be designed by the NIPH for the purpose of this study. Extracted data and laboratory results of the selected subjects will be captured in the study database.
Sponsors
GlaxoSmithKline
Study design
Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
10 Years to 25 Years
Healthy volunteers
Yes
Inclusion criteria
* Written informed consent for the ENSANUT 2012 was obtained according to local regulations from the subject/ from the parent(s)/ legally acceptable representative (LAR) of the subject. * A male or female between and including 10 and 25 years of age, who previously participated in the ENSANUT 2012 in Mexico.
Exclusion criteria
* Information required for the study is not available or incomplete. * Inadequate or insufficient serum sample to perform the laboratory tests for this study. * Serum sample is wrongly identified.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Assessment of seropositivity status (defined as the percentage of subjects with antibody titres positive) for anti-HAV | During the study (approximately 12 months) |
| Assessment of seropositivity status (defined as the percentage of subjects with antibody titres positive) for anti-HBV (Hepatitis B core antibody [anti-HBc], Hepatitis B surface antigen [HBsAg]) and Hepatitis B surface antibody (anti-HBs) | During the study (approximately 12 months) |
| Assessment of seropositivity status (defined as the percentage of subjects with antibody titres positive) for Pertussis antibodies | During the study (approximately 12 months) |
Secondary
| Measure | Time frame |
|---|---|
| Assesment of the difference in HAV, HBV and B. pertussis seropositivity rates among - Socioeconomic strata, - Regions, - Age groups, - Genders, - Risk groups, - Vaccination status for B. pertussis (if available) | During the study (approximately 12 months) |
Countries
Mexico
Outcome results
None listed